Education
About Us
Working with TipRanks
Follow Us
Progyny (PGNY)
NASDAQ:PGNY
PGNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.39 - $26.76
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.06M
Market Cap
$2.03B
Enterprise Value$1.70B
Total Cash (Recent Filing)$305.09M
Total Debt (Recent Filing)$25.50M
Price to Earnings (P/E)40.0
Beta0.79
Next Earnings
Oct 30, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding85,982,410
10 Day Avg. Volume886,152
30 Day Avg. Volume1,059,568
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit6.11
Enterprise Value/Ebitda20.51
Forecast
1Y Price Target
$27.88Price Target Upside18.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceResults came in ahead of expectations and were accompanied by a guidance raise, with the company once again benefiting from favorable utilization.
Investor ConfidenceProgyny is getting its mojo back as it tries to restore investor confidence after last year's utilization and consumption variability, and the loss of Amazon's large book-of-business.
Revenue GrowthPGNY increased 2025 revenue guidance, showing confidence in future growth despite macro uncertainties.
Bears Say
Client GrowthThe number of lives added this selling season is trailing last year's levels.
Client WinsCommentary around lower average lives per client this selling season spurred some questions around new client wins.
Stock VolatilityThe initial volatile stock reaction following the print, trading up in the after-market, then down as much as ~8%, illustrates some investor nervousness on the stock.
Progyny News
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $13.39 and its highest was $26.76 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $2.03B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Aug 07, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.158 by $0.032.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.13.
How many shares outstanding does Progyny have?
Progyny has 85,982,410 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.19 in its last earnings report, beating expectations of $0.158. Following the earnings report the stock price went down -0.911%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.88 (18.34% Upside)
$27.88 (18.34% Upside)
Blogger Sentiment
Neutral
PGNY Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 116.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $114.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.96%
12-Months-Change
Fundamentals
Return on Equity
10.94%
Trailing 12-Months
Asset Growth
8.92%
Trailing 12-Months
Company Description
Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
PGNY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates strong financial performance and growth, with record results and positive client expansion. While there are challenges such as the impact of a large client transition and slower initial pipeline build, the company's strategic initiatives and increased full-year guidance highlight a positive outlook.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$27.88
▲(18.34% Upside)
Technical Analysis
Ownership Overview
2.11% Insiders
30.83% Mutual Funds
16.46% Other Institutional Investors
25.11% Public Companies and
Individual Investors